Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
-
BBC chief resigns after row over Trump documentary
-
Norris extends title lead in Sao Paulo, Verstappen third from pit-lane
-
Norris wins in Sao Paulo to extend title lead over Piastri
-
Man City rout Liverpool to mark Guardiola milestone, Forest boost survival bid
-
Man City crush Liverpool to mark Guardiola's 1,000 match
-
Emegha fires Strasbourg past Lille in Ligue 1
-
Howe takes blame for Newcastle's travel sickness
-
Pumas maul Wales as Tandy's first game in charge ends in defeat
-
'Predator: Badlands' conquers N. American box office
-
Liga leaders Real Madrid drop points in Rayo draw
-
'Killed on sight': Sudanese fleeing El-Fasher recall ethnic attacks
-
Forest boost survival bid, Man City set for crucial Liverpool clash
-
US air travel could 'slow to a trickle' as shutdown bites: transport secretary
-
Alcaraz makes winning start to ATP Finals
-
'I miss breathing': Delhi protesters demand action on pollution
-
Just-married Rai edges Fleetwood in Abu Dhabi playoff
-
All aboard! Cruise ships ease Belem's hotel dearth
-
Kolo Muani drops out of France squad with broken jaw
-
Israel receives remains believed to be officer killed in 2014 Gaza war
-
Dominant Bezzecchi wins Portuguese MotoGP
-
Super Typhoon Fung-wong makes landfall in Philippines
-
Rai edges Fleetwood in Abu Dhabi playoff
-
Scotland sweat on Russell fitness ahead of Argentina clash
-
Faker's T1 win third back-to-back League of Legends world crown
-
Former world champion Tanak calls time on rally career
-
Ukraine scrambles for energy after Russian attacks
-
Over 1 million evacuate as deadly Super Typhoon Fung-wong nears Philippines
-
Erasmus' ingenuity sets South Africa apart from the rest
-
Asaji becomes first Japanese in 49 years to win Singapore Open
-
Vingegaard says back to his best after Japan win
-
Philippines evacuates one million, woman dead as super typhoon nears
-
Ogier wins Rally Japan to take world title fight to final race
-
A decade on, survivors and families still rebuilding after Paris attacks
-
Russia's Kaliningrad puts on brave face as isolation bites
-
Philippines evacuates hundreds of thousands as super typhoon nears
-
Syrian president arrives in US for landmark visit
-
Cyndi Lauper, Outkast, White Stripes among Rock Hall of Fame inductees
-
Fox shines in season debut as Spurs down Pelicans, Hawks humble Lakers
-
New Zealand edge West Indies by nine runs in tense third T20
-
Messi leads Miami into MLS playoff matchup with Cincinnati
-
Ukraine scrambles for energy with power generation at 'zero'
-
India mega-zoo in spotlight again over animal acquisitions
-
Messi leads Miami into MLS Cup playoff matchup with Cincinnati
-
Tornado kills six, injures 750 as it wrecks southern Brazil town
-
Minnesota outlasts Seattle to advance in MLS Cup playoffs
-
Dental Crowns 101: A Beginner's Guide
-
Marseille go top in Ligue 1 as Lens thrash Monaco
-
Fourteen-man South Africa fight back to beat France
-
Atletico, Villarreal win to keep pressure on Liga giants
-
Chelsea down Wolves to ease criticism of Maresca's rotation policy
NYSE - LSE
Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 16, 2025 / Bionoid Pharma Inc. (OTC PINK:BINP) proudly announces its corporate rebranding to AI Maverick Intel, Inc., marking a significant transformation in its strategic direction. This change underscores the company's commitment to leveraging advanced artificial intelligence technologies to revolutionize customer acquisition and engagement across healthcare, biotech, and other sectors.
The rebranding follows the successful acquisition of AI Maverick Intel, a leading platform renowned for its proprietary AI solutions that automate and enhance audience engagement. The platform's capabilities enable intelligent, two-way communication and data-driven interactions, positioning the company at the forefront of AI-driven business solutions.
"Our evolution into AI Maverick Intel, Inc. signifies more than a name change; it represents our dedication to pioneering AI technologies that drive meaningful engagement and sustainable growth," said Wayne Cockburn, CEO of AI Maverick Intel, Inc. "By integrating cutting-edge AI solutions, we are poised to deliver unparalleled value to our clients and stakeholders."
The company's flagship AI Maverick platform is designed to streamline customer acquisition processes, enabling businesses to identify, reach, and engage their target audiences with unprecedented efficiency and precision. This strategic shift aligns with the company's vision to become a leader in AI-driven solutions that foster innovation and long-term value creation.
For more information about AI Maverick Intel, Inc. and its innovative AI solutions, please visit https://aimaverickintel.com/
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. Bionoid aims to deliver long-term value through innovation, efficiency, and strategic partnerships.
Stay Connected:
Website | AI Maverick | OTC:BINP | X: @BionoidPharminc
Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN
